Constitutive expression of cyclooxygenase-2 (COX-2) and epidermal growth factor receptor
(EGFR) occurs frequently in non-small cell lung cancer (NSCLC). Anticancer research …

We performed a phase II trial to test whether a cyclooxygenase (COX-2) inhibitor, celecoxib,
added to standard first-line combination chemotherapy (CT) and as maintenance therapy …

Objectives: Preclinical observations that selective cyclooxygenase-2 inhibitors enhance in
vitro cell radiosensitivity and in vivo tumor radioresponse led to clinical trials testing …

OBJECTIVES: The cyclooxygenase 2 enzyme has become a therapeutic target in cancer
treatment. Cyclooxygenase 2 blockade with selective inhibitors increases apoptosis and …

Recently, we demonstrated that elevated expression of cyclooxygenase 2 (COX-2) is
frequently seen in a specific type of lung cancer, ie, adenocarcinoma, and is possibly …

Background Vascular endothelial growth factor (VEGF) expression is up-regulated via a
cyclooxygenase-2 (COX-2)-dependent mechanism in non-small cell lung cancer (NSCLC) …

Abstract Cyclooxygenase-2 (COX-2) is an enzyme that has been extensively investigated as
a prognostic marker in cancer. In non-small cell lung cancer (NSCLC) previous results …

Abstract Cyclooxygenase-2 (COX-2) is overexpressed in lung cancer, especially in
adenocarcinoma (ADC). Our aim was to determine the prognostic value of COX-2 on …

Purpose Increased expression of eicosanoids in cancer has been associated with adverse
prognosis. We performed a randomized phase II trial to test the hypothesis that inhibitors of …

Lung cancer is the leading cause of death from cancer in most developed nations. The most
common type of lung cancer is of non-small cell histology, representing approximately 80 …